Mostrando 2 resultados de: 2
Filtros aplicados
Subtipo de publicación
Article(2)
Área temáticas
Enfermedades(2)
Año de Publicación
2022(2)
Origen
scopus(2)
Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer
ArticleAbstract: Purpose:We investigated the pathological response rates and survival associated with 3 vs 4 cycles oPalabras claves:drug administration schedule, neoadjuvant therapy, Survival, urinary bladder neoplasmsAutores:Barocas D.A., Bivalacqua T.J., Black P.C., Cookson M.S., Dall'Era M.A., Daneshmand S., Di Trapani E., Diego M. Carrión, Dinney C.P., D’Andrea D., Grivas P.D., Holzbeierlein J.M., Kassouf W., Lotan Y., McGrath J.S., Montgomery J.S., North S., Shariat S.F., Soria F., Spiess P.E., Sridhar S.S., Stephenson A.J., Thorpe A.C., van Rhijn B.W.G., Wright J.L., Zargar H.Fuentes:scopusThe Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
ArticleAbstract: Background: There might be differential sensitivity to neoadjuvant chemotherapy (NAC) in patients wiPalabras claves:bladder cancer, Neoadjuvant chemotherapy, Primary, Response, Secondary, SurvivalAutores:Alvarez-Maestro M., Brönimann S., De Berardinis E., del Giudice F., Di Maida F., Di Trapani E., Diego M. Carrión, D’Andrea D., Filippot R., Grisay G., Hendricksen K., Krajewski W., Laukhtina E., Maggi M., Mari A., Mertens L.S., Moschini M., Paulnsteiner D., Pichler R., Pradere B., Shariat S.F., Soria F., Vallet S., van Rhijn B.W.G.Fuentes:scopus